Real-World Clinical Utility of Genome Sequencing Following the National Expansion of the Rare Disease Diagnostic Support Infrastructure in Korea

For millions of people around the world, a mysterious illness can feel like a life sentence without a name. When a child develops seizures, fails to grow, or loses the ability to speak, families often embark on a long and exhausting search for answers. This journey, known in medicine as the diagnostic odyssey, can stretch on for years. During this time, families may travel to distant cities, undergo countless tests, and spend money they do not have, all while waiting for a doctor to identify the root cause of the suffering. In many cases, the cause is a rare genetic condition, a tiny error in the body's instruction manual that disrupts how the body functions. For a long time, finding these errors was slow, expensive, and often impossible for families living far from major medical hubs.

Scientists have developed powerful tools to read this instruction manual, which is made of DNA. One method, called exome sequencing, reads only the parts of the manual that directly build proteins, which are the workhorses of the body. However, this method misses many instructions hidden in the vast spaces between those protein-building sections. A more complete method, called genome sequencing, reads the entire manual, including the hidden spaces. This allows doctors to find errors that other tests simply cannot see. The question facing healthcare systems is not just whether this technology works, but whether it can be delivered fairly to everyone, regardless of where they live, and whether it can provide answers quickly enough to change a patient's life.

In South Korea, a unique challenge exists because the majority of the population lives in the capital region, while advanced medical technology has historically been concentrated there. This created a situation where families living in rural areas or smaller cities had to travel hundreds of kilometers just to access the most advanced genetic testing. To solve this, the Korea Disease Control and Prevention Agency launched a national program to bring high-quality genome sequencing to local hospitals across the country. A new study published by a large team of researchers evaluates the first three years of this program, involving 1,620 patients. The results show that by centralizing the testing process while keeping sample collection local, the program successfully provided accurate diagnoses to patients who would otherwise have been left behind, turning a years-long struggle into a matter of weeks.

The researchers analyzed data from 1,620 participants who were enrolled in the program between 2023 and 2025. These patients came from 34 different regional medical centers, representing a wide cross-section of the country. The average age of the patients was thirteen and a half years, but many were much younger, with nearly forty percent showing symptoms before the age of two. The most common reasons for seeking help included developmental delays, seizures, and intellectual disabilities. Before joining this program, about half of the families had already tried other genetic tests, while the other half had never had any genetic testing at all. For those who had never been tested, this program was their first chance to understand the molecular cause of their condition.

The program achieved a significant success rate. Out of the 1,620 people tested, the researchers found a definitive genetic cause for 567 cases, meaning the test provided a clear answer for thirty-five percent of the group. This number is consistent with what is seen in other major studies around the world, proving that the method works reliably even when scaled up to a national level. More importantly, the answers were not just academic; for about twenty percent of the diagnosed patients, the findings led to immediate changes in how they were treated or managed. In some cases, this meant starting a specific medication, while in others, it meant changing a diet or monitoring for specific health risks. For many families, simply knowing the name of the condition was enough to stop the endless cycle of guessing and to access government support that covers the cost of care.

One of the most striking findings was how much better genome sequencing was at finding answers compared to older methods. In about nine percent of the reported genetic changes, the specific error could only be seen because the test read the entire genome. If the doctors had used the older, partial method, these errors would have been invisible. For example, the study highlighted a twelve-year-old boy who had been struggling with low potassium levels. Previous tests had found one possible cause but were not sure. The new, complete test found a second, hidden error in the same gene that the older test had missed. This second error was a small deletion that only the full-genome method could detect, finally giving the boy a definitive diagnosis. This ability to see the whole picture allowed the program to solve cases that had previously remained mysteries.

The speed of the program was another major achievement. In the past, patients in South Korea often waited more than six months for results because they had to travel to the capital, wait for a referral, and then wait for the test to be processed. The new system, which collected samples at local hospitals and sent them to a single, highly efficient central lab, reduced this wait time to an average of twenty-seven and a half days. This dramatic improvement meant that families could get answers while the patient was still young and before their condition worsened. The program also saved patients from the burden of travel, with each participant saving an average of two hundred kilometers of travel distance to the capital. This reduction in travel not only saved money but also reduced the emotional and physical stress on families who were already dealing with a sick child.

The researchers also looked at what happened after the initial test results came back. They found that the process did not end with the first report. By testing family members to see how the genetic errors were passed down, and by re-analyzing the data as medical knowledge improved, the program found even more answers. Family testing helped confirm the diagnosis in many cases, while re-analysis of the data, driven by new discoveries in medical science, turned some "inconclusive" results into positive diagnoses. This approach increased the total number of successful diagnoses by two percentage points, showing that genetic diagnosis is an evolving process rather than a one-time event.

Despite these successes, the study noted that the quality of the diagnosis varied slightly from one hospital to another. While the central lab was the same for everyone, the way doctors in different regions described the patient's symptoms and prepared the samples differed. This suggests that while the technology is ready, the human side of the process needs more standardization to ensure every patient gets the best possible care. The researchers also pointed out that the current requirement to confirm every genetic finding with a separate, older test called Sanger sequencing might be unnecessary for most cases. Their data showed that the genome sequencing results were already so accurate that the extra confirmation step was often a waste of time and resources, adding delays without improving the result.

The study concluded that a centralized, government-supported model for genome sequencing is a powerful way to deliver precision medicine to everyone, regardless of where they live. By combining local access with a central expert lab, the program dismantled the barriers that had kept many patients from getting answers. It proved that high-quality genetic testing can be fast, affordable, and effective on a national scale. For the families involved, this meant the end of a long, uncertain journey and the beginning of a path forward with a clear diagnosis. The researchers believe that this model should be expanded and supported, as it offers a blueprint for how to ensure that the benefits of modern science are shared by all members of society, not just those who live near the biggest cities.